The FDA’s advisory, from 2019, is not the first to report this contaminant’s link to cancer. NDMA has been classified by the Environmental Protection Agency (EPA) as a B2 carcinogen that has proven to cause the development of tumors in the liver and kidney. Additionally, the World Health Organization (WHO) points out that NDMA is a “potent carcinogen” and that their studies support the assumption that NDMA can cause gastric and colorectal cancer.
Initially, it was thought that the levels of NDMA that were contained within ranitidine (Zantac) products were no more severe than the consumption of cured meats. However, uring their testing process, Valisure, an independent testing laboratory, found that the impurity in some ranitidine products increases over time, and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. The company filed it’s report to the FDA (starting the current investigation). It is noted that ranitidine has NDMA in quantities over 3,000,000 ng per tablet when the daily intake limit established by the FDA stands at only 96 ng. The findings in this report mean that the amount of NDMA found in Zantac is over 30,000 times the safe amount.
Regardless of the debate around safe levels of exposure, NDMA is listed as a probable carcinogen, meaning that it is shown to increase the risk of certain cancers in humans. In this particular instance, the risks of cancer associated with Zantac, ranitidine, and NDMA are primarily gastric, or stomach, cancers.
It is important to understand that the risks of cancer associated with exposure to the levels of NDMA present in these medications were found to be serious enough to prompt a request in April 2020 from the FDA to remove all ranitidine products from the market.
How can we help you?
Ranitidine has been consumed nationwide and marketed as a safe product since its release in 1983. Many individuals have been taking Zantac for relief from heartburn, acid reflux, indigestion, and other symptoms for years or maybe even decades. People diagnosed with colorectal cancer after regularly using Zantac deserve justice, and our attorneys at Kwartler Manus, LLC are dedicated to helping them receive the compensation they deserve.
In addition to stomach cancers, there are concerns that Zantac, ranitidine, and the associated presence of NDMA may also be responsible for cancers that have developed in various parts of the human body. If you had been taking Zantac and were diagnosed as having any of the following cancers, you should speak with one of our attorneys:
Small Intestine Cancer
If you or someone you love developed colorectal cancer or any of the cancers above after regular Zantac (ranitidine) use, contact us today. Our experienced legal team can help you navigate this complicated process with ease so you can get the justice you deserve. Contact us online or call the office at (267) 214-8608 for a free consultation.